What Is “GLP-3”? How Retatrutide Got Its Internet Nickname

“GLP-3” is the internet’s nickname for retatrutide, an experimental obesity drug from Eli Lilly that switches on three hormone receptors at once: GIP, GLP-1 and glucagon. The 3 counts those receptors. There is no GLP-3 hormone in the human body.

The nickname has traveled fast. Retatrutide now draws about 271,000 Google searches a month in the US alone, according to Ahrefs, and the drug class it belongs to has become everyday news far beyond America. In India, the patent on semaglutide, the best-known GLP-1 drug, expired on 20 March 2026, and analysts quoted by the BBC expected around 50 branded generics to reach the market within months. That puts GLP-1, GIP and “GLP-3” in front of readers on several continents at once. Here is what each term means.

What does GLP stand for?

Glucagon-like peptide. The name dates to 1983, when scientists sequencing the hamster gene for glucagon found that it also coded for two related peptides with no known job. They became glucagon-like peptide 1 and glucagon-like peptide 2.

Glucagon is a pancreas hormone that raises blood sugar between meals. GLP-1 turned out to push the other way. By 1987, labs in Boston, Copenhagen and London had shown that a trimmed form of it tells the pancreas to release insulin when blood sugar is high, and only then.

GLP-2 took a different path. It is a hormone of 33 amino acids, made by cells lining the small intestine and colon, and it acts on the gut itself. In people, the family stops there. Biologists have found a GLP-3 in the elephant shark, a cartilaginous fish. None has turned up in humans.

What do the GIP, GLP-1 and glucagon receptors do?

A receptor is a docking site on the outside of a cell, shaped to fit one hormone. When the right molecule binds, the cell changes what it is doing. Retatrutide fits three of these sites, and each one runs a different part of the body’s fuel system.

  • GLP-1 receptor: found in the pancreas and in brain areas that govern hunger and fullness. Switching it on raises insulin release when blood sugar is high, slows how fast the stomach empties and lowers appetite.
  • GIP receptor: GIP is a second gut hormone released after meals. Its receptor adds to the insulin response and appears to affect how the body handles fat.
  • Glucagon receptor: glucagon raises blood sugar between meals, largely by acting on the liver. In retatrutide, this signal appears to raise energy expenditure and push the liver to burn more fat, while the other two keep glucose in check.

GIP has an awkward name of its own. It was first called gastric inhibitory polypeptide, and it now stands for glucose-dependent insulinotropic polypeptide, which describes its main job far better. All three receptors belong to the same family, and when researchers at the Shanghai Institute of Materia Medica imaged retatrutide bound to each one in 2024, the three structures were hard to tell apart.

Drug Receptors it activates Label on vendor lists
Semaglutide GLP-1 GLP-1
Tirzepatide GIP and GLP-1 GLP-2
Retatrutide GIP, GLP-1 and glucagon GLP-3, GLP-3 RT, reta

How did retatrutide get the name GLP-3?

Through peptide catalogs. Many of them count receptors, so semaglutide, which acts on one, is listed as GLP-1, tirzepatide, which acts on two, is GLP-2, and retatrutide, which acts on three, is GLP-3. No regulator or textbook uses the system.

The official names are plainer. Lilly developed the molecule under the code LY3437943, and its international nonproprietary name is retatrutide. ClinicalTrials.gov listed 34 studies under that code as of November 12, 2026, all but one sponsored by Lilly.

Sellers then added letters to tell products apart. Vendor listings now show GLP-3 RT, GLP-3 (RETA) and GLP-3 (RT), all pointing at one molecule, with RT short for retatrutide. PubChem, the US government chemistry database, even titles one of its records “Triple G.”

“Reta” is the simplest clipping of all. It turns up in vendor listings and in search boxes, and a short glossary of the term reta peptide sets out the spellings in use and the identifiers behind them.

Why can the nicknames mislead?

Because one of them collides with real biology. On a vendor list, GLP-2 means tirzepatide. In a physiology textbook, GLP-2 is the gut hormone described above, and it has nothing to do with tirzepatide, so a search for “GLP-2 peptide” mostly returns pages about the intestine.

The fix is a registry number. Retatrutide’s CAS number is 2381089-83-2, and any label that carries it describes the same 39-amino-acid chain, whatever nickname sits above it. A plain-language primer on retatrutide (GLP-3 RT) from US supplier Astral walks through that number, the molecular formula and how the chain is built.

What is retatrutide, in brief?

A synthetic peptide. Its 39 amino acids are patterned on the gut-hormone family and edited so that a single sequence can fit all three receptors. A fatty side chain attached at one point lets it bind albumin, a carrier protein in the blood, which slows its clearance enough to support once-weekly dosing. Lilly first described it in Cell Metabolism in 2022.

The trial results explain the attention. In a phase 2 trial published in the New England Journal of Medicine in June 2023, the top dose produced 24.2% average weight loss at 48 weeks, against 2.1% on placebo. In TRIUMPH-1, a phase 3 trial of 2,339 adults with obesity or overweight and no diabetes, the 12 mg dose produced 28.3% over 80 weeks, against 2.2% on placebo. Nausea affected 42.4% of people on that dose, against 14.8% on placebo.

Lilly says five phase 3 studies have come back positive. It plans to file with the FDA in the first quarter of 2027. As of November 2026, retatrutide is still investigational.

FAQs

Is GLP-3 the same as retatrutide?

On vendor lists and in online searches, yes. GLP-3 is a nickname for retatrutide that counts its three receptors, GIP, GLP-1 and glucagon. No GLP-3 hormone exists in humans.

What does reta peptide mean?

Reta is short for retatrutide. A vial sold as a reta peptide should name retatrutide or carry the CAS number 2381089-83-2.

Is retatrutide approved?

Not yet. Lilly plans to submit it to the FDA in the first quarter of 2027.

Sources

  • Eli Lilly and Company. Lilly’s triple agonist, retatrutide, delivered powerful weight loss in pivotal Phase 3 obesity trial. Press release, May 21, 2026.
  • Coskun T, et al. LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: from discovery to clinical proof of concept. Cell Metabolism, 2022.
  • Jastreboff AM, et al. Triple-hormone-receptor agonist retatrutide for obesity: a phase 2 trial. New England Journal of Medicine, 2023.
  • Irwin DM. Variation in the evolution and sequences of proglucagon and the receptors for proglucagon-derived peptides in mammals. Frontiers in Endocrinology, 2021.
  • BBC News. India’s cheap weight-loss drugs could reshape global obesity fight. Republished by The Star (Kenya), March 18, 2026.